» Articles » PMID: 16368725

Evidence of Bias in Estimates of Influenza Vaccine Effectiveness in Seniors

Overview
Journal Int J Epidemiol
Specialty Public Health
Date 2005 Dec 22
PMID 16368725
Citations 188
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Numerous observational studies have reported that seniors who receive influenza vaccine are at substantially lower risk of death and hospitalization during the influenza season than unvaccinated seniors. These estimates could be influenced by differences in underlying health status between the vaccinated and unvaccinated groups. Since a protective effect of vaccination should be specific to influenza season, evaluation of non-influenza periods could indicate the possible contribution of bias to the estimates observed during influenza season.

Methods: We evaluated a cohort of 72,527 persons 65 years of age and older followed during an 8 year period and assessed the risk of death from any cause, or hospitalization for pneumonia or influenza, in relation to influenza vaccination, in periods before, during, and after influenza seasons. Secondary models adjusted for covariates defined primarily by diagnosis codes assigned to medical encounters.

Results: The relative risk of death for vaccinated persons compared with unvaccinated persons was 0.39 [95% confidence interval (95% CI), 0.33-0.47] before influenza season, 0.56 (0.52-0.61) during influenza season, and 0.74 (0.67-0.80) after influenza season. The relative risk of pneumonia hospitalization was 0.72 (0.59-0.89) before, 0.82 (0.75-0.89) during, and 0.95 (0.85-1.07) after influenza season. Adjustment for diagnosis code variables resulted in estimates that were further from the null, in all time periods.

Conclusions: The reductions in risk before influenza season indicate preferential receipt of vaccine by relatively healthy seniors. Adjustment for diagnosis code variables did not control for this bias. In this study, the magnitude of the bias demonstrated by the associations before the influenza season was sufficient to account entirely for the associations observed during influenza season.

Citing Articles

All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data.

Alessandria M, Malatesta G, Di Palmo G, Cosentino M, Donzelli A F1000Res. 2025; 13:886.

PMID: 40028449 PMC: 11868741. DOI: 10.12688/f1000research.154058.2.


A Double Machine Learning Approach for the Evaluation of COVID-19 Vaccine Effectiveness Under the Test-Negative Design: Analysis of Québec Administrative Data.

Jiang C, Talbot D, Carazo S, Schnitzer M Stat Med. 2025; 44(5):e70025.

PMID: 39985144 PMC: 11845851. DOI: 10.1002/sim.70025.


Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025.

Blanquart F, Vieillefond V, Visseaux B, Abou Chakra C, Nunes M, Jacques A Euro Surveill. 2025; 30(7).

PMID: 39980426 PMC: 11843621. DOI: 10.2807/1560-7917.ES.2025.30.7.2500074.


Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza in elderly Chinese patients with diabetes: A test-negative design case-control study.

Chen Z, Yang T Hum Vaccin Immunother. 2025; 21(1):2458814.

PMID: 39885661 PMC: 11792806. DOI: 10.1080/21645515.2025.2458814.


Double Negative Control Inference in Test-Negative Design Studies of Vaccine Effectiveness.

Li K, Shi X, Miao W, Tchetgen Tchetgen E J Am Stat Assoc. 2024; 119(547):1859-1870.

PMID: 39524693 PMC: 11545655. DOI: 10.1080/01621459.2023.2220935.